Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Neurology. Genetics|July 12, 2021
Brain Regional Differences in Hexanucleotide Repeat Length in X-Linked Dystonia-Parkinsonism Using Nanopore SequencingCharles Jourdan Reyes, Björn-Hergen Laabs, Susen Schaake, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 11, 2020
DNA Methylation as a Potential Molecular Mechanism in X-linked Dystonia-ParkinsonismChristin Krause, Susen Schaake, Karen Grütz, et al.
Neurorehabilitation and Neural Repair|February 29, 2012
Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trialRaymond L Rosales, Keng He Kong, Khean Jin Goh, et al.
The International Journal of Neuroscience|November 5, 2010
The unique phenomenology of sex-linked dystonia parkinsonism (XDP, DYT3, "Lubag")Lillian V Lee, Corazon Rivera, Rosalia A Teleg, et al.
The Lancet. Neurology|June 9, 2019
Parkinson's disease in the Western Pacific RegionShen-Yang Lim, Ai Huey Tan, Azlina Ahmad-Annuar, et al.
Brain : a Journal of Neurology|April 28, 2022
Mosaic divergent repeat interruptions in XDP influence repeat stability and disease onsetJoanne Trinh, Theresa Lüth, Susen Schaake, et al.
Movement Disorders Clinical Practice|November 27, 2025
Practices, Resources and Challenges in Parkinson's Disease Management in Asia: Movement Disorders in Asia Study Group ReportNorlinah Mohamed Ibrahim, Warongporn Phuenpathom, Priya Jagota, et al.
Annals of Neurology|January 16, 2023
Basal Ganglia Atrophy as a Marker for Prodromal X-Linked Dystonia-ParkinsonismHenrike Hanssen, Cid C E Diesta, Marcus Heldmann, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 31, 2026
Iatrogenic botulism: a risk for botulinum toxin's medical use?Dirk Dressler, Jürgen Frevert, Eric A Johnson, et al.
Pageof 8